Halozyme Therapeutics Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2018 | $34.9M | $248.9M | $57.9M |
| FY2019 | $383.0M | $91.8M | $120.2M |
| FY2020 | $0 | $151.0M | $147.7M |
| FY2021 | $787.3M | $197.0M | $118.7M |
| FY2022 | $1.49B | $169.8M | $234.2M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2018 | $34.9M | $248.9M | $57.9M |
| FY2019 | $383.0M | $91.8M | $120.2M |
| FY2020 | $0 | $151.0M | $147.7M |
| FY2021 | $787.3M | $197.0M | $118.7M |
| FY2022 | $1.49B | $169.8M | $234.2M |